{
  "cohort": "ER+/HER2- MBC, 2L, Medicare, Abemaciclib, by Age (2024–2025)",
  "insight_type": "Age Group Variation",
  "summary": "Patients 75+ have only 14% abemaciclib utilization, 10% below Medicare average. Addressing concerns in this age group could yield $34,000/year.",
  "chart": {
    "type": "bar",
    "unit": "age_group",
    "data": [
      { "name": "65-74", "value": 32, "gap": 8, "highlight": false },
      { "name": "75+", "value": 14, "gap": -10, "highlight": true }
    ],
    "benchmark": 24,
    "nccn_target": 24
  },
  "financial_impact": {
    "annual_opportunity": "$34,000/year",
    "math": "$34,000/year = 9 elderly patients × $3,800 margin per patient"
  },
  "clinical_impact": {
    "description": "Elderly patients benefit from appropriate CDK4/6i use with modified dosing.",
    "quantitative": "+5.2 months PFS"
  },
  "peer_comparison": {
    "description": "Patients 75+ have only 14% abemaciclib utilization, 21% below top-performing peers. Leading institutions achieve 35% utilization in this age group with proper support. Closing this gap could yield $79,800/year.",
    "peer_benchmark": 35,
    "financial_impact": {
      "annual_opportunity": "$79,800/year",
      "math": "$79,800/year = 21 elderly patients × $3,800 margin per patient"
    },
    "action_steps": [
      "Establish geriatric oncology consultation for all 75+ CDK4/6i candidates",
      "Implement peer-developed dosing protocols for elderly patients",
      "Create 75+ CDK4/6i champion program with top-performing providers",
      "Develop specialized support resources for elderly patients on CDK4/6i"
    ]
  },
  "weighted_score": 72,
  "action_steps": [
    "Implement dose modification protocols for elderly patients",
    "Educate providers on managing abemaciclib side effects in 75+ patients",
    "Assign geriatric oncology navigator to 75+ patients"
  ],
  "suggestions": [
    "Develop elderly-specific CDK4/6i management pathway"
  ],
  "drilldowns": []
} 